PaxMedica, Inc. Common Stock
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrom… Read more
Market Cap & Net Worth: PaxMedica, Inc. Common Stock (PXMD)
PaxMedica, Inc. Common Stock (PINK:PXMD) has a market capitalization of $25.13K ($25.13K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #47172 globally and #14627 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PaxMedica, Inc. Common Stock's stock price $0.00 by its total outstanding shares 125633870 (125.63 Million).
PaxMedica, Inc. Common Stock Market Cap History: 2022 to 2025
PaxMedica, Inc. Common Stock's market capitalization history from 2022 to 2025. Data shows change from $4.34 Billion to $25.13K (-99.30% CAGR).
PaxMedica, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PaxMedica, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PXMD by Market Capitalization
Companies near PaxMedica, Inc. Common Stock in the global market cap rankings as of March 18, 2026.
Key companies related to PaxMedica, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
PaxMedica, Inc. Common Stock Historical Marketcap From 2022 to 2025
Between 2022 and today, PaxMedica, Inc. Common Stock's market cap moved from $4.34 Billion to $ 25.13K, with a yearly change of -99.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $25.13K | -99.79% |
| 2024 | $11.94 Million | -87.45% |
| 2023 | $95.10 Million | -97.81% |
| 2022 | $4.34 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of PaxMedica, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $25.13K USD |
| MoneyControl | $25.13K USD |
| MarketWatch | $25.13K USD |
| marketcap.company | $25.13K USD |
| Reuters | $25.13K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.